Here’s how Trump might approach his drug pricing plan
President Trump is expected to advance a “most-favored nation” policy to lower drug prices. How effective might it be? The devil will be in the details.
Related Articles
To understand why investors rejoiced at Trump’s attack on drug firms, think like a pharma CEO
President Trump could have walked softly and carried a big stick. As pharmaceutical investors see it, he instead stomped loudly and wielded a wet noodle.
UnitedHealth swaps CEOs, suspends 2025 outlook
UnitedHealth said Tuesday its CEO Andrew Witty had stepped down, as the company also suspended its 2025 outlook
Investment firm RA Capital lays off incubator staff amid industry instability, push into China
Biotech investment firm RA Capital has laid off staff at its internal startup incubator, highlighting the instability among VCs as the biotech industry struggles to…
To understand why investors rejoiced at Trump’s attack on drug firms, think like a pharma CEO
President Trump could have walked softly and carried a big stick. As pharmaceutical investors see it, he instead stomped loudly and wielded a wet noodle.
Why new wellness-branded energy drinks have health experts worried
The $22 billion energy drink industry is tapping into the aesthetics of health and wellness to reach new demographics and continue its exponential growth.
‘What do we do with uncertainty?’ A former CDC director’s advice to new physicians and scientists
“The lines between fact, science, and uncertainty are increasingly blurred. Things once treated as dogma are being questioned. Things that were once uncertain are too…
Amid the Milwaukee lead crisis, a laid-off CDC scientist volunteered his expertise. It wasn’t so simple
After his job was cut, a CDC scientist volunteered to help Milwaukee respond to the lead crisis in its public schools. For now, he’s in…
Elizabeth Holmes rises again — or at least her partner does
The emergence of Haemanthus, a company formed by Elizabeth Holmes’ partner, Billy Evans, triggered a mix of shock, anger, and rueful skepticism.
Appeals court reopens the question of who owns patents for groundbreaking CRISPR discovery
A federal appeals court said the patent office made legal errors in awarding foundational patents for CRISPR-Cas9 to the Broad Institute
Beyond politics, even U.S. vaccine experts may envision fewer Covid shots in the future
For years, U.S. vaccine experts have issued a universal recommendation for Covid vaccines. That could change soon.